Pathstone Family Office’s Eledon Pharmaceuticals ELDN Stock Holding History

Pathstone Family Office’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$17.9K	Buy	+13,029	New	+$17.4K	﹤0.01%	1650

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return

Pathstone Family Office's ELDN Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Eledon Pharmaceuticals (ELDN) in Q3 2023: 13,029 shares worth $17.9K. The stake represents ﹤0.01% of the portfolio and ranks #1650 among its holdings.

28 funds tracked by Wall St. Rank hold ELDN as of Q3 2023.

Pathstone Family Office held 13,029 shares of Eledon Pharmaceuticals worth $17.9K as of Q3 2023.
Eledon Pharmaceuticals was a new Pathstone Family Office position in Q3 2023.
Eledon Pharmaceuticals made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1650 holding.
28 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.